Self-perceived non-celiac wheat sensitivity (NCWS) questionnaire in psoriasis patients
To identify psoriasis patients reporting a self-perceived NCWS; all patients will be asked to answer, consecutively, to a validated questionnaire for the self-assessment of wheat and other foods' intolerance. This is a questionnaire self-compiled by patients consisting of three sections: 1) general information (eg. age, sex, highest completed education level, etc.) 2) wheat-related symptoms (sore 0 = no symptoms, score = 1, symptoms after wheat intake; if score = 1 other question qualitatively inquire the symptoms evoked by wheat intake, eg. what kind of symptoms, how long patient perceive this problem, etc.); 3) other foods-related symptoms (score 0 = no symptoms, score 1 = symptoms after intake of other foods; if score = 1 other question qualitatively inquire the symptoms evoked by the intake of the specific food reported by the patients, eg. what kind of symptoms, how long patient perceive this problem, etc.)
Effect of WFD plus CMPFD in changing symptoms of psoriasis patients as assessed by BSA
To assess the effect that a WFD plus CMPFD determines in symptoms of patients affected with psoriasis the following score will be used: Body Surface Area (BSA), representing the percentage of cutaneous area affected by psoriasis.
Effect of WFD plus CMPFD in changing symptoms of psoriasis patients as assessed by Psoriasis Area Severity Index
To assess the effect that a WFD plus CMPFD determines in symptoms of patients affected with psoriasis the following score will be used: Psoriasis Area Severity Index (PASI), a composite evaluation for psoriasis severity, subscoring for erythema, induration, scaling, and percentage of body-surface area affected. The rating scale includes 4 levels: No Psoriasis, Mild Psoriasis, Moderate Psoriasis, and Severe Psoriasis.
Effect of WFD plus CMPFD in changing symptoms of psoriasis patients as assessed by IGA
To assess the effect that a WFD plus CMPFD determines in symptoms of patients affected with psoriasis the following score will be used: Investigator's Global Assessment (IGA), a 5-point instrument for rating the clinician's impression of the overall severity of the psoriasis, from 0, clear skin, to 4, severe disease.
Effect of WFD plus CMPFD in changing symptoms of psoriasis patients as assessed by GSRS
To assess the effect that a WFD plus CMPFD determines in symptoms of patients affected with psoriasis the following score will be used: Gastrointestinal Symptom Rating Scale (GSRS), assessment scale for irritable bowel syndrome-like and functional dyspepsia-like symptoms, providing for a score ranging from 15 to 60).
Effect of WFD plus CMPFD in changing symptoms of psoriasis patients as assessed by Extraintestinal symptoms rating scale.
To assess the effect that a WFD plus CMPFD determines in symptoms of patients affected with psoriasis the following score will be used: Extraintestinal symptoms rating scale, a scoring system based on the symptoms most frequently observed in NCWS patients, providing for a score ranging from 9 to 34.
Effect of WFD plus CMPFD in changing Quality of Life (QoL) of psoriasis patients.
To assess the effect that a WFD plus CMPFD determines in QoL of patients affected with psoriasis, both of the intervention and the control group. The following score will be used: Dermatology Life Quality Index (DLQI, a validated instrument to evaluate quality of life for skin disease, providing for a score ranging from 0 to 30 points, with higher scores indicating a greater effect on quality of life).
Effect of open wheat challenge in symptoms changing of psoriasis patients as assessed by BSA
To evaluate, by an open wheat challenge, the frequency of a coexistent NCWS condition in psoriasis patients, both of the intervention group (T2int) and the control group (T3con). The following score will be used: Body Surface Area (BSA), representing the percentage of cutaneous area affected by psoriasis.
Effect of open wheat challenge in symptoms changing of psoriasis patients as assessed by Psoriasis Area Severity Index
To evaluate, by an open wheat challenge, the frequency of a coexistent NCWS condition in psoriasis patients, both of the intervention group (T2int) and the control group (T3con). the following score will be used: Psoriasis Area Severity Index (PASI), a composite evaluation for psoriasis severity, subscoring for erythema, induration, scaling, and percentage of body-surface area affected. The rating scale includes 4 levels: No Psoriasis, Mild Psoriasis, Moderate Psoriasis, and Severe Psoriasis.
Effect of open wheat challenge in symptoms changing of psoriasis patients as assessed by IGA.
To evaluate, by an open wheat challenge, the frequency of a coexistent NCWS condition in psoriasis patients, both of the intervention group (T2int) and the control group (T3con). The following score will be used: Investigator's Global Assessment (IGA), a 5-point instrument for rating the clinician's impression of the overall severity of the psoriasis, from 0, clear skin, to 4, severe disease.
Effect of open wheat challenge in symptoms changing of psoriasis patients as assessed by GSRS.
To evaluate, by an open wheat challenge, the frequency of a coexistent NCWS condition in psoriasis patients, both of the intervention group (T2int) and the control group (T3con).The following score will be used: Gastrointestinal Symptom Rating Scale (GSRS), assessment scale for irritable bowel syndrome-like and functional dyspepsia-like symptoms, providing for a score ranging from 15 to 60).
Effect of open wheat challenge in symptoms changing of psoriasis patients as assessed by Extraintestinal symptoms rating scale.
To evaluate, by an open wheat challenge, the frequency of a coexistent NCWS condition in psoriasis patients, both of the intervention group (T2int) and the control group (T3con). The following score will be used: Extraintestinal symptoms rating scale, a scoring system based on the symptoms most frequently observed in NCWS patients, providing for a score ranging from 9 to 34.
Effect of open wheat challenge in Quality of Life (QoL) changing of psoriasis patients.
To assess the effect that an open wheat challenge determines in QoL of patients affected with psoriasis, both of the intervention (T2int) and the control group (T3con). The following score will be used: DLQI (a validated instrument to evaluate quality of life for skin disease, providing for a score ranging from 0 to 30 points, with higher scores indicating a greater effect on quality of life).
Erythrocyte sedimentation rate (ESR) changing in psoriasis and NCWS patients.
Laboratory blood analysis will be performed to assess erythrocyte sedimentation rate (ESR)
C-reactive protein (CRP) changing in psoriasis and NCWS patients.
Laboratory blood analysis will be performed to assess C-reactive protein (CRP)
Complete blood count changing in psoriasis and NCWS patients.
Laboratory blood analysis will be performed to assess complete blood count
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-1β
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-2
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-4
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-5
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-6
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-8
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-10
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-17A
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-22
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interleukin (IL)-23,
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: Tumor Necrosis Factor (TNF)-α
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: interferon (IFN)-γ
Peripheral blood ELISA analysis of inflammatory cytokines changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of inflammatory cytokines pattern will be performed to assess: Toll-Like Receptor (TLR)-4.
Peripheral blood cytofluorimetric analysis to evaluate expression of lymphocytes typical of psoriasis
Peripheral blood cytofluorimetric analysis will be performed to assess expression of lymphocytes typical of psoriasis pathogenetic pattern [i.e., T helper (Th)17, and T cytotoxic (Tc)17].
Peripheral blood ELISA analysis of intestinal permeability markers changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of intestinal permeability markers will be performed to assess: zonulin
Peripheral blood ELISA analysis of intestinal permeability markers changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of intestinal permeability markers will be performed to assess: F-Actin
Peripheral blood ELISA analysis of intestinal permeability markers changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of intestinal permeability markers will be performed to assess: intestinal fatty acid-binding protein (i-FABP)
Peripheral blood ELISA analysis of intestinal permeability markers changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of intestinal permeability markers will be performed to assess: lipopolysaccharide (LPS)
Peripheral blood ELISA analysis of intestinal permeability markers changing in psoriasis and NCWS patients.
Peripheral blood ELISA analysis of intestinal permeability markers will be performed to assess: LPS-binding protein (LBP)
Lactulose(LA)/Mannitol(MA) test changing in psoriasis and NCWS patients.
LA/MA test will be performed to assess in vivo intestinal permeability.
Fecal ELISA analysis of inflammatory gut marker changing in psoriasis and NCWS patients.
Fecal ELISA analysis of inflammatory gut marker will be performed to assess fecal calprotectin.
Gut microbiota changing in psoriasis and NCWS patients.
Gut microbiota assessment will be performed by analysis and quantification of gut microbioma on stools samples. After fecal collection, bacterial DNA will be extracted by cetyltrimethyl ammonium bromide. A simple and inexpensive physical lysis method for DNA and RNA extraction from freshwater microalgae and 16S ribosomal ribonucleic acid (rRNA) sequencing will be performed by polymerase chain reaction (PCR) methods, using universal primers. The resulting fragments will be then sequenced by pyrosequencing. Each reading will be compared with a database of known 16S rRNA sequences, using the BLAT program by phylogenetically assigning the most specific and reliable nodes. This method of assigning the obtained data leads to a "weighted" phylogenetic tree that characterizes well the bacterial content of the sample.